FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
16.0 pts (24h)GeopolíticaOne-OffHealth & Medicine3m
KalshiVerificar disponibilidadeKYC obrigatório2% de taxaDados de resolução verificadosRazoavelmente calibradoProbabilidade implícita atual
Sim 98%+16.0pt
Qualidade do mercado
44 / 100
Baixa qualidadeVolume 24h
511 €
Liquidez
156,7 €
Baixa liquidezCompra / Venda
80.0% / 88.0%
Spread
8.0 pt
Spread amploDados do mercado
Atualizado há 5 minutos
17/06/26, 21:00 UTC1/01/27, 04:59 UTC
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiDid COVID-19 come from a laboratory?
Manifold MarketsWhich states will report local cases in the May 2026 Ebola Bundibugyo outbreak
Manifold MarketsWhen, where or how will Trump die?
Manifold MarketsRegras
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Liquida via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting protein is chemically linked to a potent cancer-killing payload.
- The targeting protein homes in on a molecule called B7-H3 (also known as CD276), which appears in unusually high amounts on the surface of many cancer cells, and once the drug locks onto that target it is pulled inside the cell and releases its toxic payload.
- In doing so, it aims to kill tumor cells more precisely than traditional chemotherapy, which attacks both healthy and cancerous cells indiscriminately.
Mercados abertos
Geopolitics
POLYMARKETWhich party will gain most seats in Russian Parliamentary Election?
- United Russia (ER)+5.0pt75%
- New People (NL)-4.1pt21%
- Liberal Democratic Party of Russia (LDPR)-1.1pt3%
+5 mais resultados
- Volume total
- € 22,2 mi
- Volume 24h
- € 470,8 mil
POLYMARKETUS announces end of Iranian blockade by which date?
- December 31-2.3pt48.3%
- October 31-2.0pt29.3%
- September 30-4.0pt12.1%
+17 mais resultados
POLYMARKETUS x Iran Effective Ceasefire begins by...? (2 week pause)
- September 30+1.0pt80%
- September 18+1.0pt75%
- September 11+6.5pt70%
+2 mais resultados
POLYMARKETWill China invade Taiwan by end of 2026?
- No-0.2pt96%
- Yes+0.2pt4%
- Volume total
- € 35,3 mi
- Volume 24h
- € 100,1 mil
POLYMARKETIsrael x Iran ceasefire continues through which date?
- July 18+0.3pt100%
- July 20+0.1pt100%
- July 22+0.5pt100%
+20 mais resultados
POLYMARKETKharg Island no longer under Iranian control by which date?
- December 317%
- September 30+0.1pt1%
- July 310%
+7 mais resultados
- Volume total
- Nobel Peace Prize Winner 2026
- US-Iran nuclear deal?
- Russia x Ukraine peace talks by which date?
- Strait of Hormuz traffic returns to normal by December 31?
- Will the U.S. invade Iran before 2027?
- Bab el-Mandeb Strait effectively closed by which date?
- What will Trump say during RNC Convention (Night 2)?
- Russia x Ukraine ceasefire agreement by which date?
- Iran-Oman Hormuz Management Agreement by which date?
- Will the Iranian regime fall by September 30?
Perguntas frequentes
- Quais são as probabilidades atuais de FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- A Kalshi cota Yes em 98% em 8 de setembro de 2026.
- Quando FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) é resolvido?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) deverá ser resolvido em 1 de janeiro de 2027.
- Como FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) é liquidado?
- A Kalshi liquida este mercado da seguinte forma: If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.